Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
Medtronic
McKinsey
AstraZeneca

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,422,223

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,422,223 protect, and when does it expire?

Patent 9,422,223 protects ORENITRAM and is included in one NDA.

This patent has eighteen patent family members in seven countries.

Summary for Patent: 9,422,223
Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC), Jeffs; Roger (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:14/881,379
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Delivery;

Drugs Protected by US Patent 9,422,223

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-001 Dec 20, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-002 Dec 20, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-003 Dec 20, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-004 Dec 20, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-005 Oct 7, 2016 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,422,223

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2526534   Start Trial
Canada 2736406   Start Trial
Canada 2851309   Start Trial
Canada 2959852   Start Trial
China 100558351   Start Trial
China 101265226   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
Moodys
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.